Our project will run for a five-year period, with the clinical trial at its heart. The trial will launch in mid-2018 with the first patients recruited from the UK. We plan to recruit 40 MCDS patients across the whole trial, from centres in the UK, Australia, France, Belgium, and Italy, all of whom will receive the drug under investigation.
Alongside the clinical trial, the MCDS-Therapy project will work to develop new chemical measures of the disease, called biomarkers, that will help to determine treatment success. We will also investigate the financial cost of MCDS to patients, healthcare providers, and society, as well as its impact on people’s lives. This type of work will help to demonstrate the need for an effective treatment, but also help us to assess the cost-effectiveness of using carbamazepine to treat MCDS. This will help to ensure that any successfully developed treatment will be paid for by healthcare providers, meaning it reaches the patients that need it. We will share our progress with you throughout the project, through this website, social media, and our mailing list, so please do get involved with our work.